low-dose methotrexate
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
10
Adverse Effects of Low-Dose Methotrexate in Patients with Rheumatoid Arthritis
5
Low-Dose Methotrexate Inhibits Methionine S-Adenosyltransferase In Vitro and In Vivo
10
Oral events related to low-dose methotrexate in rheumatoid arthritis patients
6
Single Low-Dose Methotrexate-Induced Fatal Pancytopenia: Case Report and Review of the Literature
5
Low-dose methotrexate was first demonstrated to be a. Understanding the Mechanisms of Action of Methotrexate
6
Low-dose methotrexate in myeloproliferative neoplasm models
25
A Rapidly Fatal Case of Low-Dose Methotrexate Toxicity
5
The Effects of Low Dose Methotrexate on Metabolism in Primary Human PBMCs
307
Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate
5
Low dose Methotrexate Therapy for Intravenous Immunoglobulin resistant Kawasaki Disease
5
In vitro inhibition of HUVECs by low dose methotrexate – insights into oral adverse events
7
Serosal complications of single-agent low-dose methotrexate used in gestational trophoblastic diseases: first reported case of methotrexate-induced peritonitis
5
QUANTITATIVE LIVER FUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH LOW-DOSE METHOTREXATE: A LONGITUDINAL STUDY
7
Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate: efficacy, acute and long-term effects
5
Similar short term clinical response to high dose versus low dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis
6
Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis
6
Low-dose methotrexate in sickle-cell disease: a pilot study with rationale borrowed from rheumatoid arthritis
11
Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease
6
Clinical Outcomes of Low Dose Methotrexate Therapy as a Second Line Drug for Intravenous Immunoglobulin Resistant Kawasaki Disease
6